Evidence map›Paper›PMID 41134248›Full record

ArticleJACC. Basic to translational science2025

CD14 Blockade Modulates Macrophage-Mediated Immunological Injury in a Translational Model of Reperfused ST-Segment Elevation Myocardial Infarction.

Aascha A D'Elia Nee Brown, Helen Kiriazis, Jason Bloom, Jonathan Noonan, Ian Hsu, Gabriella E Farrugia, Haoyun Fang, Stephanie Jansen, Natalia Carvajal, Crisdion Krstevski and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Aascha A D'Elia Nee BrownTranslational Cardiology Centre, Baker Heart and Diabetes Institute, Melbourne, Australia.
Helen KiriazisTranslational Cardiology Centre, Baker Heart and Diabetes Institute, Melbourne, Australia; Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia.
Jason BloomHeart Failure Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; Department of Cardiology, Alfred Hospital, Melbourne, Australia.
Jonathan NoonanBaker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia; Atherothrombosis and Vascular Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; School of Translational Medicine, Monash University, Melbourne, Australia.
Ian HsuCardiac Cellular Systems Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Gabriella E FarrugiaCardiac Cellular Systems Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Haoyun FangMolecular Proteomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Stephanie JansenAlfred Medical Research and Education Precinct Animal Services, Melbourne, Australia.
Natalia CarvajalMonash Sequencing, Monash University, Melbourne, Australia.
Crisdion KrstevskiCardiac Cellular Systems Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Waled A ShihataHeart Failure Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Yow Keat ThamBaker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia; School of Translational Medicine, Monash University, Melbourne, Australia; Cardiac Hypertrophy Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Melbourne, Victoria, Australia.
Angela VaisMonash Histology, Monash University, Melbourne, Australia.
Camilla CohenMonash Histology, Monash University, Melbourne, Australia.
Adam C ParslowBaker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia; Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Melbourne, Victoria, Australia; Baker Institute Microscopy Platform, Baker Heart and Diabetes Institute, Melbourne, Australia.
Chad JohnsonBioimaging Platform, La Trobe University, Melbourne, Australia.
Anita C ThomasTranslational Cardiology Centre, Baker Heart and Diabetes Institute, Melbourne, Australia; Department of Cardiology, Alfred Hospital, Melbourne, Australia.
Malathi S I DonaCardiac Cellular Systems Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Kyah GrigolonTranslational Cardiology Centre, Baker Heart and Diabetes Institute, Melbourne, Australia.
Scott J Y LohTranslational Cardiology Centre, Baker Heart and Diabetes Institute, Melbourne, Australia.
Guy KrippnerTranslational Cardiology Centre, Baker Heart and Diabetes Institute, Melbourne, Australia; Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia.
David K WrightDepartment of Neuroscience, Monash University, Melbourne, Australia.
Bing H WangSchool of Translational Medicine, Monash University, Melbourne, Australia; Biomarker Discovery Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Antonio AbbateRobert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, Virginia, USA.
Junedh AmruteDepartments of Medicine, Pathology and Immunology, and Developmental Biology, Washington University School of Medicine, St Louis, Missouri, USA.
Kory LavineDepartments of Medicine, Pathology and Immunology, and Developmental Biology, Washington University School of Medicine, St Louis, Missouri, USA.
Mark W ApplebyImplicit Bioscience Ltd, Brisbane, Australia and Seattle, Washington, USA.
David CroweImplicit Bioscience Ltd, Brisbane, Australia and Seattle, Washington, USA.
Garry RedlichImplicit Bioscience Ltd, Brisbane, Australia and Seattle, Washington, USA.
Brian W ZiegelaarImplicit Bioscience Ltd, Brisbane, Australia and Seattle, Washington, USA.
Julie R McMullenBaker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia; School of Translational Medicine, Monash University, Melbourne, Australia; Cardiac Hypertrophy Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; Department of Physiology, Monash University, Melbourne, Australia.
David W GreeningBaker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia; School of Translational Medicine, Monash University, Melbourne, Australia; Molecular Proteomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Melbourne, Victoria, Australia.
Alexander R PintoBaker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia; School of Translational Medicine, Monash University, Melbourne, Australia; Cardiac Cellular Systems Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Melbourne, Victoria, Australia.
David M KayeHeart Failure Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia; Department of Cardiology, Alfred Hospital, Melbourne, Australia; School of Translational Medicine, Monash University, Melbourne, Australia. Electronic address: david.kaye@baker.edu.au.
Daniel G DonnerTranslational Cardiology Centre, Baker Heart and Diabetes Institute, Melbourne, Australia; Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia; Department of Cardiology, Alfred Hospital, Melbourne, Australia; School of Translational Medicine, Monash University, Melbourne, Australia. Electronic address: daniel.donner@baker.edu.au.

Funding

Specification and Function of Tissue Resident and Recruited Macrophages in Cardiac Remodeling and Heart FailureR35HL161185 · NHLBI · WASHINGTON UNIVERSITY · PI Kory J. Lavine · 2022 to 2026
$4.3M
NHLBI NIH HHS R35 HL161185
6 · The paper itself

Abstract

These preclinical trials provide the first evidence of cluster of differentiation 14 (CD14) blockade with a murine analogue of atibuclimab, a CD14-neutralizing antibody, preventing secondary immunological exacerbation of cardiac injury in a translational mouse model of reperfused ST-segment elevation myocardial infarction (STEMI), assessed using multiple clinical modalities. Multiomic studies suggest CD14 blockade downregulated macrophage-specific proinflammatory and tissue-wide remodeling processes without suppression of monocyte-macrophage infiltration or repair. These findings support a clinically practicable targeted immunomodulatory strategy of CD14 blockade initiated at reperfusion to prevent chronic immunological progression toward ischemic heart failure, and provide new insights into the pleiotropic roles of CD14 in inflammation and myocardial injury.

Indexed as

antibody therapyCD14heart failureimmunomodulationmyocardial infarction

Identifiers

PMID41134248
PMCPMC12790148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.